Pinned Tweet
Proud to share the first Canadian real-world experience with publicly funded #LuPSMA617. A true multiD effort at @pmcancercentre and @UHN! Grateful to all collaborators, referring MDs, and our patients. @PMResearch_UHN @UHN_Research mdpi.com/1718-7729/33/11/666
@CurrentOncology
thank you @urotoday for highlighting our decade experience with NAC followed by TMT for MIBC at @pmcancercentre
urotoday.com/recent-abstract…
thank you to Meghan, @kalasri3, our amazing multiD team, and all collaborators
looking forward to more trials in this space
Maria Jiang retweeted
Less bureaucracy, more efficient and patient-centered clinical research, without compromising safety or data integrity @JCOOA_ASCO
@myESMO & @ASCO Consensus @TeresaSAmaral
ascopubs.org/doi/pdf/10.1200…
Maria Jiang retweeted
Oncology needs leaders who connect people, champion collaboration, and advance cancer care beyond borders. @montypal brings that vision and commitment
Proud to support his candidacy for the @ASCO Board of Directors! #ASCOElection 🗳️
asco.org/about-asco/asco-ove…
🤖 Made with AI
Maria Jiang retweeted
Voting for @PGrivasMDPhD - a generous, gregarious and outstanding GU Med Onc who would be a fantastic part of @ASCO Nominating Committee.
Voting for ASCO Election is open! I am so honored to run among other great candidates for ASCO nominating committee. We are all very excited to serve ASCO mission, vision & broader community! Visit asco.org/election to learn more about all candidates and cast your vote!
Maria Jiang retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
Maria Jiang retweeted
Voting for ASCO Election is open! I am so honored to run among other great candidates for ASCO nominating committee. We are all very excited to serve ASCO mission, vision & broader community! Visit asco.org/election to learn more about all candidates and cast your vote!
Voting in the ASCO Election is open now until December 2! Meet the candidate for President-Elect, @teekayowo MD, PhD, FASCO.
Learn more about Dr. Owonikoko and make your voice heard: bit.ly/4zi4KWm
Maria Jiang retweeted
TROFUSE-055 is a randomized phase 3 non-muscle invasive bladder cancer trial. It’s another trial exploring bladder surgery sparing approaches. This study tests the combination of SAC-TMT with Pembro (68% RR in advanced disease) followed by chemoradiation. The control is ChemoRT (+/- NAC). This study is distinct from EV309 where no chemoRT is given in the study arm. We will need many trials to identify the optimal approach. The role of chemoRT in ADC driven cCR is unknown. @OncoAlert
Maria Jiang retweeted
FDA grants Priority Review for the VOLGA trail, in which 3 neoadjuvant cycles of EV and a year of Perioperative durvalumab was given for patients with muscle invasive bladder cancer. Press release states an EFS and OS advantage. Data will be presented #ESMO26 @OncoAlert @myESMO @Annals_Oncology astrazeneca-us.com/content/a…
Maria Jiang retweeted
⚡️ @NEJM - Perioperative enfortumab vedotin + pembrolizumab improves outcomes in muscle-invasive bladder cancer.
In KEYNOTE-905:
• 2-year EFS: 74.7% vs 39.4% (HR 0.40)
• OS: HR 0.50
• pCR: 57.1% vs 8.6%
A potential new standard in cisplatin-ineligible patients.
#BladderCancer #Immunotherapy
nejm.org/doi/full/10.1056/NE…
Maria Jiang retweeted
We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability. Not new—just better applied. Study in @NEJM by the #Stampede group/@MRCCTU
nejm.org/doi/full/10.1056/NE…
Maria Jiang retweeted
ctDNA data for radiotherapy (TMT) in muscle invasive bladder cancer shows 19/59 pts (32%) were ctDNA+ve at baseline (⬇️ than in NIAGARA 57%). 11/19 had ctDNA clearance with TMT. Those that didn’t clear had ⬆️ risk of systemic rather than local relapse, underlining TMTs role in local rather than systemic control. CtDNA helps. Congrats to the team. @OncoAlert
Maria Jiang retweeted
⚡️ ctDNA after bladder-sparing trimodality therapy in MIBC.
In 84 patients treated with chemoradiotherapy, detectable post-CRT plasma ctDNA strongly correlated with metastatic recurrence, but not with isolated local relapse.
Supports ctDNA as a marker of distant relapse risk.
@CCR_AACR #BladderCancer #ctDNA #MIBC
aacrjournals.org/clincancerr…
Maria Jiang retweeted
Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer pfizer.com/news/press-releas…
Maria Jiang retweeted
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery
Maria Jiang retweeted
Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from @pmcancercentre .
Maria Jiang retweeted
The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active.
✅ No dose-limiting toxicities
💪 PSA-50% decline in 55%
🧬 Supports future α+β theranostic combos.
🔗 authors.elsevier.com/a/1lyc6…
Congrats @LouiseKostos: what an amazing PhD!
Thank-you to @PCF_Science @pros_tic @Bayer for funding & support, co-senior author @AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.
Maria Jiang retweeted
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj @PCFnews @OncoAlert @urotoday
Maria Jiang retweeted
Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?
Maria Jiang retweeted
📬 The Milan Consensus paper on Clinical CR definition & Endpoints for next-gen bladder-sparing trials is out in @JCO_ASCO @ASCO | following the @SanRaffaeleMI #GURetreat24
Co-sponsored by @IBCG_BladderCA @GTumors
It was a tremendous multidisciplinary effort involving friends/KOL from various fields, pt advocates @BladderCancerUS @WorldBladderCan Pharma Industries & @FDA #EMA proving insights
✅ cCR should be rigorously based on imaging + biopsy + urinary citology
✅cCR still immature as primary endpoint for registration trials (good for esploratory studies)
✅ EFS good for registration trials
✅ EFS should capture ANY type of event including HG bladder relapses
🛜 role of biomarkers (ctDNA/utDNA) still to conceive in this clinical setting but likely to become the next 🧩
@MyUniSR @UroDocAsh @SpiessPhilippe @sonpavde #MattGalsky @#bladdercancer #endpoints #clinicalresearch @urotoday @OncLive @OncoAlert @Larvol








































